Similar to the pre-treatment setting, reduced tumor growth after systemic ROCKi treatment (Figure 5K) was associated with loss of melanoma cell roundness (Figure 5L), decreased F4/80+CD206+ TAM infiltration (Figure 5M), and decreased vasculature (Figure 5N) in the IFs. The gene discussed is MRC1; the disease is melanoma.